{"id":746182,"date":"2023-04-10T08:04:37","date_gmt":"2023-04-10T12:04:37","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-to-present-at-the-22nd-annual-needham-virtual-healthcare-conference\/"},"modified":"2023-04-10T08:04:37","modified_gmt":"2023-04-10T12:04:37","slug":"ovid-therapeutics-to-present-at-the-22nd-annual-needham-virtual-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-to-present-at-the-22nd-annual-needham-virtual-healthcare-conference\/","title":{"rendered":"Ovid Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">NEW YORK, April  10, 2023  (GLOBE NEWSWIRE) &#8212; Ovid Therapeutics Inc. (NASDAQ: OVID), a \u00a0biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today announced that management will present at the 22<sup>nd<\/sup> Annual Needham Virtual Healthcare Conference on April 17, 2023 at 11:00 a.m. ET.<\/p>\n<p align=\"justify\">A live webcast of the presentation can be accessed through the Events &amp; Presentations section of the Company\u2019s website at investors.ovidrx.com. An archived replay of the webcast will be available on the Company\u2019s website following the live presentation.<\/p>\n<p align=\"justify\">\n        <strong>About Ovid Therapeutics<\/strong><br \/>\n        <br \/>Ovid Therapeutics Inc. is a New York-based biopharmaceutical company striving to conquer seizures and brain disorders with courageous science. Ovid\u2019s pipeline of small molecule and genetic medicines candidates seek to meaningfully improve the lives of people and families affected by epilepsies and seizure-related disorders. Ovid is developing OV329, a GABA-aminotransferase inhibitor, for the potential treatment of treatment-resistant seizures, and OV350, a direct activator of the KCC2 transporter, for potential treatment of epilepsies. In addition, Ovid maintains a significant financial interest in the future regulatory development and potential commercialization of soticlestat, which Takeda is responsible for advancing globally. Soticlestat is a cholesterol 24-hydroxylase inhibitor, which is currently in Phase 3 trials for Dravet and Lennox-Gastaut syndromes. For more information about these and other Ovid research programs, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=CwjcbJ9xbUkzyFIETJ6IDlpy22fGPpgBi3BIE6cMzUYmnpqMoL9LaEk2APIg4oBgM15tlMHAQ0VubmUQbUCrtQ==\" rel=\"nofollow noopener\" target=\"_blank\">www.ovidrx.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>This press release includes certain disclosures that contain \u201cforward-looking statements,\u201d including, without limitation: the potential development and use of OV329, OV350 and the status of Takeda\u2019s two pivotal Phase 3 trials evaluating soticlestat for Lennox-Gastaut and Dravet syndromes. You can identify forward-looking statements because they contain words such as \u201canticipates,\u201d \u201cbelieves,\u201d \u201cexpected,\u201d \u201cintends,\u201d \u201cplan,\u201d \u201cpotential,\u201d and \u201cwill,\u201d and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Forward-looking statements are based on Ovid\u2019s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, uncertainties inherent in the preclinical and clinical development and regulatory approval processes, the risk that Ovid may not be able to realize the intended benefits of its technology. Additional risks that could cause actual results to differ materially from those in the forward-looking statements are set forth under the caption \u201cRisk Factors\u201d in Ovid\u2019s Quarterly Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 13, 2023, and in future filings Ovid makes with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Ovid assumes no obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.<\/p>\n<p align=\"justify\">\n        <strong>Contacts<\/strong><br \/>\n        <br \/>\n        <strong>Investors and Media:<\/strong><br \/>\n        <br \/>Ovid Therapeutics Inc.<br \/>Meg Alexander<br \/>917-943-6681<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Q4fTPlADfeTQ8iEJQu_bfQklsKORL8g82oPinSD2YqSn6RFkxrSGi2bONMHRIf7qW1VPlBhZ8wGN4YVdJNrczCI1X9jIkx64hAekw7YCOhQ=\" rel=\"nofollow noopener\" target=\"_blank\">malexander@ovidrx.com<\/a><\/p>\n<p align=\"justify\">OR<\/p>\n<p align=\"justify\">\n        <strong>Investors:<\/strong><br \/>\n        <br \/>Argot Partners<br \/>Maeve Conneighton<br \/>212-596-7231<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=UFJGFmMyBi-iXFP8Uqg7MFUoGX9hSEVX0Ht06vcpATia-WTKIOXMW-f7ezF2IAZ16Td9N72ZbCJiw2ds4hdEqST6xSWU1q620hWTqaWxs2E=\" rel=\"nofollow noopener\" target=\"_blank\">ovid@argotpartners.com<\/a><\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwMzY5OSM1NTE0NjY5IzIwNzAyNjA=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MTE0ZjNmZWQtZTViZS00OWNiLWFhOTQtMmQ5YmI0ZjYxMzE2LTEwODE4MzE=\/tiny\/Ovid-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, April 10, 2023 (GLOBE NEWSWIRE) &#8212; Ovid Therapeutics Inc. (NASDAQ: OVID), a \u00a0biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today announced that management will present at the 22nd Annual Needham Virtual Healthcare Conference on April 17, 2023 at 11:00 a.m. ET. A live webcast of the presentation can be accessed through the Events &amp; Presentations section of the Company\u2019s website at investors.ovidrx.com. An archived replay of the webcast will be available on the Company\u2019s website following the live presentation. About Ovid Therapeutics Ovid Therapeutics Inc. is a New York-based biopharmaceutical company striving to conquer seizures and brain disorders with courageous science. Ovid\u2019s pipeline of small molecule and genetic &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-to-present-at-the-22nd-annual-needham-virtual-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Ovid Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-746182","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ovid Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-to-present-at-the-22nd-annual-needham-virtual-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ovid Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, April 10, 2023 (GLOBE NEWSWIRE) &#8212; Ovid Therapeutics Inc. (NASDAQ: OVID), a \u00a0biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today announced that management will present at the 22nd Annual Needham Virtual Healthcare Conference on April 17, 2023 at 11:00 a.m. ET. A live webcast of the presentation can be accessed through the Events &amp; Presentations section of the Company\u2019s website at investors.ovidrx.com. An archived replay of the webcast will be available on the Company\u2019s website following the live presentation. About Ovid Therapeutics Ovid Therapeutics Inc. is a New York-based biopharmaceutical company striving to conquer seizures and brain disorders with courageous science. Ovid\u2019s pipeline of small molecule and genetic &hellip; Continue reading &quot;Ovid Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-to-present-at-the-22nd-annual-needham-virtual-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-10T12:04:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwMzY5OSM1NTE0NjY5IzIwNzAyNjA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ovid-therapeutics-to-present-at-the-22nd-annual-needham-virtual-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ovid-therapeutics-to-present-at-the-22nd-annual-needham-virtual-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Ovid Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference\",\"datePublished\":\"2023-04-10T12:04:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ovid-therapeutics-to-present-at-the-22nd-annual-needham-virtual-healthcare-conference\\\/\"},\"wordCount\":532,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ovid-therapeutics-to-present-at-the-22nd-annual-needham-virtual-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwMzY5OSM1NTE0NjY5IzIwNzAyNjA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ovid-therapeutics-to-present-at-the-22nd-annual-needham-virtual-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ovid-therapeutics-to-present-at-the-22nd-annual-needham-virtual-healthcare-conference\\\/\",\"name\":\"Ovid Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ovid-therapeutics-to-present-at-the-22nd-annual-needham-virtual-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ovid-therapeutics-to-present-at-the-22nd-annual-needham-virtual-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwMzY5OSM1NTE0NjY5IzIwNzAyNjA=\",\"datePublished\":\"2023-04-10T12:04:37+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ovid-therapeutics-to-present-at-the-22nd-annual-needham-virtual-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ovid-therapeutics-to-present-at-the-22nd-annual-needham-virtual-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ovid-therapeutics-to-present-at-the-22nd-annual-needham-virtual-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwMzY5OSM1NTE0NjY5IzIwNzAyNjA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwMzY5OSM1NTE0NjY5IzIwNzAyNjA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ovid-therapeutics-to-present-at-the-22nd-annual-needham-virtual-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ovid Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ovid Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-to-present-at-the-22nd-annual-needham-virtual-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Ovid Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference - Market Newsdesk","og_description":"NEW YORK, April 10, 2023 (GLOBE NEWSWIRE) &#8212; Ovid Therapeutics Inc. (NASDAQ: OVID), a \u00a0biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today announced that management will present at the 22nd Annual Needham Virtual Healthcare Conference on April 17, 2023 at 11:00 a.m. ET. A live webcast of the presentation can be accessed through the Events &amp; Presentations section of the Company\u2019s website at investors.ovidrx.com. An archived replay of the webcast will be available on the Company\u2019s website following the live presentation. About Ovid Therapeutics Ovid Therapeutics Inc. is a New York-based biopharmaceutical company striving to conquer seizures and brain disorders with courageous science. Ovid\u2019s pipeline of small molecule and genetic &hellip; Continue reading \"Ovid Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-to-present-at-the-22nd-annual-needham-virtual-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2023-04-10T12:04:37+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwMzY5OSM1NTE0NjY5IzIwNzAyNjA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-to-present-at-the-22nd-annual-needham-virtual-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-to-present-at-the-22nd-annual-needham-virtual-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Ovid Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference","datePublished":"2023-04-10T12:04:37+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-to-present-at-the-22nd-annual-needham-virtual-healthcare-conference\/"},"wordCount":532,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-to-present-at-the-22nd-annual-needham-virtual-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwMzY5OSM1NTE0NjY5IzIwNzAyNjA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-to-present-at-the-22nd-annual-needham-virtual-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-to-present-at-the-22nd-annual-needham-virtual-healthcare-conference\/","name":"Ovid Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-to-present-at-the-22nd-annual-needham-virtual-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-to-present-at-the-22nd-annual-needham-virtual-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwMzY5OSM1NTE0NjY5IzIwNzAyNjA=","datePublished":"2023-04-10T12:04:37+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-to-present-at-the-22nd-annual-needham-virtual-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-to-present-at-the-22nd-annual-needham-virtual-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-to-present-at-the-22nd-annual-needham-virtual-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwMzY5OSM1NTE0NjY5IzIwNzAyNjA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwMzY5OSM1NTE0NjY5IzIwNzAyNjA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-to-present-at-the-22nd-annual-needham-virtual-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Ovid Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/746182","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=746182"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/746182\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=746182"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=746182"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=746182"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}